Oct 2026· The Journal of Pediatric Pharmacology and Therapeutics· Vol 31 5, pp.
675-679
· 0 citations· 12 references
Medicine
TL;DR
This is the first published case describing cefepime PK in an adolescent on iHD and demonstrates the utility of model-informed precision dosing in this population.
Abstract
There are no studies evaluating cefepime pharmacokinetics (PK) in pediatric patients receiving intermittent hemodialysis (iHD). Cefepime dosing in this population is particularly challenging owing to several variables that can affect clearance, including dialysis prescription, residual kidney function, fluid overload, and systemic inflammation. We describe cefepime PK parameters and concentration time profiles in an adolescent male undergoing iHD for whom a cefepime PK consult was requested. Using model-informed precision dosing, we were able to ensure the patient's current dosing of cefepime at 1000 mg daily maintained estimated free cefepime concentrations above 4 times the minimum inhibitory concentration (MIC) for MICs up to ∼4 mg/L while avoiding excessively high trough concentrations. Despite suspicion for increasing residual kidney function, due to increasing urine output, the patient's PK parameters were very similar 4 months later, when an additional consult was requested. This is the first published case describing cefepime PK in an adolescent on iHD and demonstrates the utility of model-informed precision dosing in this population.
Background/Objectives: Cefazolin is a first-generation cephalosporin antibiotic widely used for the treatment and prophylaxis of bacterial infections in both adult and pediatric populations. It is predominantly eliminated unchanged by the kidneys. Impaired renal function can reduce its clearance and increase systemic e...
Abdelrahman Abdeen, Yousef A. Bin Jardan, Najia Rahim et al.· Pharmaceutics· 0 citations
ABSTRACT Cefepime is used in critically ill pneumonia patients, but dosing in renal replacement therapy (RRT) is complicated by altered renal function, extracorporeal removal, and variability in pulmonary epithelial lining fluid (ELF) exposure. We sought to develop an integrated model linking systemic, extracorporeal,...
Adrian Valadez, Emma Harlan, Marc H. Scheetz et al.· Antimicrobial Agents and Che...· 0 citations
Historical therapeutic drug monitoring (TDM) strategies for intravenous tobramycin in people with cystic fibrosis (pwCF) were developed in the pre-CFTR modulator era and relied predominantly on clearance-based monitoring to minimise toxicity. Contemporary pwCF demonstrate greater variability in body composition and cli...
Ellie Johnson, Michael G. Williams, D. Henderson et al.· European Journal of Clinical...· 0 citations
BACKGROUND
Vancomycin dosing remains challenging due to narrow therapeutic window and pharmacokinetic (PK) variability in critically ill children. This study aims to characterise pediactric vancomycin PK, identify significant covariates, and optimise dosing strategies.
METHODS
Vancomycin plasma concentrations from pa...
T. Dorofaeff, Xin Liu, E. Novy et al.· International Journal of Ant...· 0 citations
In children with multiple organ dysfunction syndrome (MODS), vancomycin dosing is frequently guided by population-based approaches followed by therapeutic drug monitoring that requires considerable blood volumes. We sought to develop a population pharmacokinetic (PK) model and describe vancomycin exposures using blood-...
Marc H. Scheetz, Justin Shiau, Victor Amajor et al.· International Journal of Ant...· 0 citations
AIMS
Cefepime is commonly used in critically ill children for whom there is a high between-subject variability. To reach the therapeutic pharmacokinetic (PK) target in critically ill patients, prolonged infusion of beta-lactams seems to be the most efficient. The aim of this study was to compare cefepime exposure betwe...
Mark J. Hobeika, D. Hirt, Emmanuelle Bille et al.· British Journal of Clinical...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.